Literature DB >> 23754163

Reciprocal effects of Guizhi decoction to the Guizhi decoction syndrome by toll-like receptor mRNA expression and cytokines secretion.

Xin-liang Du1, Feng Sui, Hai-ru Huo, Hong-wei Zhang, Kan Luo, Lan-fang Li, Shu-ying Guo, Ting-liang Jiang.   

Abstract

OBJECTIVE: To explore the pathological mechanisms of Guizhi Decoction () syndrome and the therapeutic molecular mechanisms of the Guizhi Decoction, Mahuang Decoction (), Sangju Decoction ( ) and Yinqiao Powder (), as well as the potentially biological basis that Guizhi Decoction is most effective only for the patients with Guizhi Decoction syndrome in clinical practice.
METHODS: We first got serum samples from the patients suffering from both upper respiratory tract infection and Guizhi Decoction syndrome identified by the doctors of Chinese medicine (CM) in the clinic. Four formulas with therapeutic actions of pungent warmth or pungent coolness for superficial syndromes were chosen and four kinds of rat serum samples each containing one of the above-mentioned herbal formulas were collected, then the effects of Guizhi Decoction syndromes' patient serum as well as the effects of sera containing the formulas after being stimulated by the patient serum samples on both the mRNA expression of certain toll-like receptor (TLR) subtypes and the release of some inflammatory cytokines in RAW264.7 cells were tested and analyzed in vitro.
RESULTS: The expression of TLR-3, TLR-4 and TLR-9 mRNA among the 9 tested TLR subforms were up-regulated in the macrophages stimulated by the sera from untreated upper respiratory infection patients with the Guizhi Decoction syndrome (symptomcomplex). The products such as interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and interferon (IFN)-β from stimulated macrophages through TLR signaling pathways were also increased correspondingly. Interestingly, the changes induced by the Guizhi Decoction syndrome patients' sera were masked significantly after the macrophages were incubated with the sera from donors treated with Guizhi Decoction. Similarly, the three other exterior-releasing formulas were all effective in reversing the up-regulated changes of certain TLR subforms to different degrees, but both the number of targeted TLRs and efficacy of them seemed to be inferior to that of Guizhi Decoction.
CONCLUSION: Evidence from these experiments might contribute to the scientific explanation of both the pharmacological mechanisms of Guizhi Decoction and also the CM theory that Guizhi Decoction is specifically prescribed for the treatment of Guizhi Decoction syndrome (The gearing formula to the symptom-complex).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23754163     DOI: 10.1007/s11655-013-1325-2

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  23 in total

1.  Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor.

Authors:  K Burns; J Clatworthy; L Martin; F Martinon; C Plumpton; B Maschera; A Lewis; K Ray; J Tschopp; F Volpe
Journal:  Nat Cell Biol       Date:  2000-06       Impact factor: 28.824

2.  TLR11 activation of dendritic cells by a protozoan profilin-like protein.

Authors:  Felix Yarovinsky; Dekai Zhang; John F Andersen; Gerard L Bannenberg; Charles N Serhan; Matthew S Hayden; Sara Hieny; Fayyaz S Sutterwala; Richard A Flavell; Sankar Ghosh; Alan Sher
Journal:  Science       Date:  2005-04-28       Impact factor: 47.728

Review 3.  Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors.

Authors:  Francois Romagne
Journal:  Drug Discov Today       Date:  2006-11-28       Impact factor: 7.851

Review 4.  Therapeutic targeting of toll-like receptors in gastrointestinal inflammation.

Authors:  Shunji Ishihara; Mohammad A K Rumi; Cesar-F Ortega-Cava; Hideaki Kazumori; Yasunori Kadowaki; Norihisa Ishimura; Yoshikazu Kinoshita
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

5.  Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis.

Authors:  Monica Marta; Asa Andersson; Magnus Isaksson; Olle Kämpe; Anna Lobell
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

Review 6.  Role of phosphoinositide 3-kinase in innate immunity.

Authors:  Kaoru Hazeki; Kiyomi Nigorikawa; Osamu Hazeki
Journal:  Biol Pharm Bull       Date:  2007-09       Impact factor: 2.233

7.  Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity.

Authors:  Mino Yoshioka; Nobuyuki Fukuishi; Yuichi Kubo; Hiroyuki Yamanobe; Kanae Ohsaki; Yoshiko Kawasoe; Mana Murata; Aya Ishizumi; Yumiko Nishii; Nobuaki Matsui; Masaaki Akagi
Journal:  Biol Pharm Bull       Date:  2008-02       Impact factor: 2.233

8.  TLR-9 activation aggravates concanavalin A-induced hepatitis via promoting accumulation and activation of liver CD4+ NKT cells.

Authors:  Wei Jiang; Rui Sun; Rongbin Zhou; Haiming Wei; Zhigang Tian
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

9.  Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.

Authors:  Parviz Ahmad-Nejad; Hans Häcker; Mark Rutz; Stefan Bauer; Ramunas M Vabulas; Hermann Wagner
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

10.  Effects of 3-phenyl-propenal on the expression of toll-like receptors and downstream signaling components on raw264.7 murine macrophages.

Authors:  Bao-Sheng Zhao; Hai-Ru Huo; Yue-Ying Ma; Hong-Bin Liu; Lan-Fang Li; Feng Sui; Cang-Hai Li; Shu-Ying Guo; Ting-Liang Jiang
Journal:  Am J Chin Med       Date:  2008       Impact factor: 4.667

View more
  3 in total

1.  Gyeji-tang water extract exerts anti-inflammatory activity through inhibition of ERK and NF-κB pathways in lipopolysaccharide-stimulated RAW 264.7 cells.

Authors:  Sae-Rom Yoo; Yeji Kim; Mee-Young Lee; Ohn-Soon Kim; Chang-Seob Seo; Hyeun-Kyoo Shin; Soo-Jin Jeong
Journal:  BMC Complement Altern Med       Date:  2016-10-12       Impact factor: 3.659

2.  To Predict Anti-Inflammatory and Immunomodulatory Targets of Guizhi Decoction in Treating Asthma Based on Network Pharmacology, Molecular Docking, and Experimental Validation.

Authors:  Rui Sun; Gonghao Xu; Dongyang Gao; Qi Ding; Yuanyuan Shi
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-20       Impact factor: 2.629

3.  Gui-zhi decoction for allergic rhinitis: A protocol for systematic review and meta analysis.

Authors:  Bin Zou; Wentao Zhang; Yuechuan Cai; Fubing Zhang; Chengrui Wang
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.